LLA — LungLife AI Share Price
Last trade - 00:00- £0.69m
- -£1.12m
- $0.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.35 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.12 | ||
| Price to Tang. Book | 0.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 31.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.7% | ||
| Return on Equity | -48.59% | ||
| Operating Margin | -15941.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.21 | 0.2 | 0.02 | 0.05 | 2.05 | 0.5 | -39.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. The Company’s diagnostic, the LungLB test, is used as a tool to provide clinicians with additional information to help in the decision-making process for people with indeterminate lung nodules following a CT scan. The LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 30th, 2009
- Public Since
- July 8th, 2021
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 30,658,603
- Address
- 2545 W. Hillcrest Drive, Suite 140, THOUSAND OAKS, 91320
- Web
- https://lunglifeai.com/
- Phone
- +1 8054099868
- Auditors
- Crowe U.K. LLP
Similar to LLA
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 21:50 UTC, shares in LungLife AI are trading at 7.00p. This share price information is delayed by 15 minutes.
Shares in LungLife AI last closed at 7.00p and the price had moved by -76.67% over the past 365 days. In terms of relative price strength the LungLife AI share price has underperformed the FTSE All Share Index by -77.31% over the past year.
The overall consensus recommendation for LungLife AI is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLungLife AI does not currently pay a dividend.
LungLife AI does not currently pay a dividend.
LungLife AI does not currently pay a dividend.
To buy shares in LungLife AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 7.00p, shares in LungLife AI had a market capitalisation of £0.69m.
Here are the trading details for LungLife AI:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: LLA
Based on an overall assessment of its quality, value and momentum LungLife AI is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in LungLife AI is 170.16p. That is 2330.85% above the last closing price of 7.00p.
Analysts covering LungLife AI currently have a consensus Earnings Per Share (EPS) forecast of -$0.14 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LungLife AI. Over the past six months, its share price has underperformed the FTSE All Share Index by -53.56%.
As of the last closing price of 7.00p, shares in LungLife AI were trading -48.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The LungLife AI PE ratio based on its reported earnings over the past 12 months is 23.35. The shares last closed at 7.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
LungLife AI's management team is headed by:
- Simon Raab - CHM
- Sara Barrington - CEO
- Paul Pagano - VRD
- Frederick Gluck - DRC
- James McCullough - DRC